# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
LogicBio Therapeutics (NASDAQ:LOGC) reported quarterly losses of $(0.18) per share. This is a 41.94 percent increase over losse...
-SEC Filing
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announ...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing around 270 points on Monday.
Gainers
LogicBio Therapeutics's (NASDAQ:LOGC) short percent of float has fallen 62.5% since its last report. The company recently r...
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by...
U.S. stocks extended gains midway through trading, with the Dow Jones gaining more than 600 points on Monday.